Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary hypertension is a substantial global health issue. All age groups are affected with
rapidly growing importance in elderly people, particularly in countries with ageing …

Pulmonary hypertension (PH) is frequent in left heart disease (LHD), as a consequence of
the underlying condition. Significant advances have occurred over the past 5 years since the …

Transcatheter aortic valve implantation (TAVI) has spawned the evolution of novel catheter-
based therapies for a variety of cardiovascular conditions. Newer device iterations are …

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it
remains a life-shortening condition. There have been significant advances in imaging …

In patients with aortic and/or mitral valve disease the presence of pulmonary hypertension
(PH) indicates a decompensated state of the disease with left ventricular and left atrial …

In the summer of 2016, delegates from the German Society of Cardiology (DGK), the
German Respiratory Society (DGP), and the German Society of Pediatric Cardiology (DGPK) …

Background There are limited data on the prognostic impact of periprocedural pulmonary
hypertension (PH) after transcatheter aortic valve replacement (TAVR). Objectives The aim …

Aims Pulmonary hypertension (PH) is a relevant complication of left heart disease (LHD).
The 2015 ESC/ERS PH guidelines report two different haemodynamic subsets of PH due to …

Objectives: The authors investigated the development of pulmonary hypertension (PH),
predictors of PH regression, and its prognostic impact on short, mid-, and long-term …